ClinicalTrials.gg
CompletedNCT07940634CAND-PERIOUpdated Nov 17, 2026

Subgingival Candida Colonization in Smokers and Non-Smokers With Periodontitis

An observational study in Periodontitis, sponsored by Atlas University. Completed at 1 site in Turkey (Türkiye). Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Atlas University · Observational

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
186
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 264 studies in Periodontitis with a site in Turkey — 37 open to participants now, 51 under way, none of them phase 3. Periodontitis · Turkey.

Enrollment
16th of 148
186 · median 80
Started
2018
with 14 others
Observational
148 of 264
23 open now
Registered
262nd of 264
by date

Among the 264 studies in Periodontitis with a site in Turkey, this one is the 16th largest by enrollment of the 148 observational ones that give a count, is one of 15 that started in 2018, is one of 148 observational ones, and was the 262nd registered.

Periodontitis

1,239 studies on the registry are indexed under Periodontitis; 302 are open to participants now.

Browse Periodontitis studies →

Open to participants now

37 of the 264 studies in Periodontitis with a site in Turkey are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 162 Periodontitis studies recruiting now, 79 (49%) set no upper age limit and 62 (38%) stop at 75 or younger; 12 take children under 18; 79 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 264 studies in Periodontitis with a site in Turkey, or all of them as a file.
02

Study summary

This observational cross-sectional study evaluates the presence and distribution of Candida species in the subgingival area of smokers and non-smokers with Stage II periodontitis. Participants are grouped according to their smoking status. Periodontal clinical parameters, including plaque index, gingival index, bleeding on probing, probing depth, and clinical attachment level, are recorded.

Subgingival samples are collected from selected incisor and molar teeth. Candida species isolated from these samples are identified using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). The study aims to determine whether smoking is associated with differences in the frequency, distribution, and species profile of subgingival Candida colonization in patients with periodontitis.

Read the detailed description

Periodontitis is a multifactorial inflammatory disease associated with a complex subgingival microbial community. Although bacterial microorganisms are the main focus of periodontal research, fungi such as Candida species may also be present in periodontal pockets and may contribute to the subgingival microbial environment.

Smoking is an established risk factor for periodontal disease and may alter the ecological conditions of the oral cavity. These changes may affect the colonization and persistence of Candida species in periodontal sites. The purpose of this cross-sectional observational study is to evaluate the quantitative and qualitative distribution of subgingival Candida species in smokers and non-smokers diagnosed with generalized Stage II Grade B periodontitis.

Participants are categorized into smoker and non-smoker groups according to their smoking status. Periodontal examinations include assessment of plaque index, gingival index, bleeding on probing, probing depth, and clinical attachment level.

Subgingival microbiological samples are collected from teeth #16, #21, #36, and #41. Samples obtained from single-rooted and multi-rooted teeth are processed separately. Candida growth is assessed using culture methods, and isolated colonies are identified at the species level using MALDI-TOF MS.

The study compares Candida positivity between smokers and non-smokers and evaluates differences according to tooth type and Candida species. The relationships between Candida colonization and clinical periodontal parameters are also assessed.

03

Conditions studied

  • Periodontitis

Keywords

  • Candida
  • Candida albicans
  • Smoking
  • Periodontal disease
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults diagnosed with generalized Stage II Grade B periodontitis who were evaluated at the Department of Periodontology, Faculty of Dentistry, Istanbul Aydin University. Participants were categorized as smokers or non-smokers according to their smoking status and underwent periodontal clinical examination and subgingival sampling for Candida assessment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Diagnosis of generalized Stage II Grade B periodontitis according to the 2017 World Workshop classification.

Individuals classified as smokers or non-smokers according to their smoking status.

Ability to undergo periodontal clinical examination and subgingival sampling. Provision of written .

Exclusion criteria

Exclusion Criteria:

Systemic diseases that may influence the progression of periodontitis. Recent periodontal treatment. Pregnancy or lactation. Prolonged use of antibiotics or . History of candidiasis. Use of antifungal medications. Physical limitations restricting normal oral hygiene procedures. Smoking 10 or more cigarettes per day.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
186 participants (actual)
Patient registry
No

Groups and cohorts

  • Smokers

    Participants diagnosed with generalized Stage II Grade B periodontitis who were classified as smokers according to their smoking status.

    Other: Observational

  • Non-Smokers

    Participants diagnosed with generalized Stage II Grade B periodontitis who were classified as non-smokers according to their smoking status.

    Other: Observational

Interventions

  • OtherObservational

    Current cigarette smoking was evaluated as an observational exposure and was not assigned by the investigators. Participants in the smoker group reported smoking fewer than 10 cigarettes per day. Smoking status was self-reported, and no smoking-related intervention or treatment was administered as part of the study.

06

What researchers measure

Primary outcomes

  1. Prevalence of Subgingival Candida Colonization

    The proportion of participants with detectable Candida species in subgingival samples was determined using culture followed by species identification with MALDI-TOF MS and compared between smokers and non-smokers with Stage II Grade B periodontitis.

    Time frame: At the baseline study visit

Secondary outcomes

  1. Distribution of Candida Species

    The distribution of Candida species identified in subgingival samples, including Candida albicans, Candida dubliniensis, Candida glabrata, and Candida kefyr, was evaluated using MALDI-TOF MS.

    Time frame: At the baseline study visit

07

Study locations

1 site
  • Istanbul Aydin University, Faculty of Dentistry
    Istanbul, Istanbul 34295, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared because no data-sharing plan was established for this study, and participant-level data are subject to confidentiality and ethical requirements.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in Apr 2018, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 17, 2026
StartActual
Jan 5, 2018
Primary completionActual
Apr 30, 2018
CompletionActual
Jun 1, 2018
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07940634
Lead sponsor
Atlas University
Responsible party
Aysenur Arpaci (research assistant, Atlas University) — Principal investigator
First posted
Nov 17, 2026
Start date
Jan 5, 2018
Primary completion
Apr 30, 2018
Completion
Jun 1, 2018
Last update
Nov 17, 2026

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion